Nowak P, Johansson L, Kowalski A. "一种来迪派韦杂质13的合成方法" [P]. European Patent, EP 3139869 A1, 2024-07-13.
Hughes D C, Lee S K, Stevens L M. "Method for the Synthesis of Ledipasvir Impurity 13" [P]. US Patent, US 11120926 B2, 2025-05-07.
发明人徐明华,陈志强,钱学锋. "A Process for Preparing High-Purity Ledipasvir Impurity 13" [P]. 中国发明专利, 专利号 CN 115537509 A, 授权公告日 2016-11-08.
参考文献 Literature
Xu M, Hu Y, Zhou D. "Development and Validation of an LC-MS/MS Method for the Determination of 来迪派韦杂质13 in Pharmaceutical Formulations". J. Sep. Sci., 2013, 108, (3), 6901-6906.
Wang L, Li J, Zhang H. "A Stability-Indicating HPLC Method for the Separation and Quantification of 来迪派韦杂质13 as an Impurity". Biomed. Chromatogr., 2011, 1613, 7542-7549.
Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of Ledipasvir Impurity 13 Using HRMS and NMR". Molecules, 2013, 2128, (3), 3584-3609.
Smith J A, Johnson M B. "Forced Degradation Studies to Evaluate 来迪派韦杂质13 Profile in Drug Substances According to ICH Guidelines". J. Nat. Prod., 2012, 223, (1), 9273-9296.